Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutations could triple risk of late miscarriage:

This article was originally published in Clinica

Executive Summary

Mutations in the genes encoding two coagulants, factor V and prothrombin, could triple the risk of late miscarriage during pregnancy, according to a study published in The New England Journal of Medicine (October 5). Dr Martinelli and colleagues from the University of Milan, Italy, assessed 67 women with unexplained late miscarriages and 232 controls. They found that 16% of the patients had either the factor V or prothrombin mutation. The researchers concluded that screening for these mutations should be conducted in women who suffer from late miscarriages. However, they warned that further studies are required to determine the potential benefit of anticoagulant therapy in these patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel